133 related articles for article (PubMed ID: 7590597)
1. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
Yokoyama T
Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
[TBL] [Abstract][Full Text] [Related]
2. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
3. Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40.
Raptis L; Brownell HL; Corbley MJ; Wood KW; Wang D; Haliotis T
Cell Growth Differ; 1997 Aug; 8(8):891-901. PubMed ID: 9269898
[TBL] [Abstract][Full Text] [Related]
4. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N
J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
[TBL] [Abstract][Full Text] [Related]
5. Alternate mechanisms of ras activation are complementary and favor and formation of ras-GTP.
Patel G; MacDonald MJ; Khosravi-Far R; Hisaka MM; Der CJ
Oncogene; 1992 Feb; 7(2):283-8. PubMed ID: 1549350
[TBL] [Abstract][Full Text] [Related]
6. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Tokumitsu Y; Nakano S; Ueno H; Niho Y
J Cell Physiol; 2000 May; 183(2):221-7. PubMed ID: 10737897
[TBL] [Abstract][Full Text] [Related]
7. Isolation of azatyrosine-induced revertants from ras-transformed human mammary epithelial cells.
Kyprianou N; Taylor-Papadimitriou J
Oncogene; 1992 Jan; 7(1):57-63. PubMed ID: 1741165
[TBL] [Abstract][Full Text] [Related]
8. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
9. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
Kaplan JB
Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
[TBL] [Abstract][Full Text] [Related]
10. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
Shantz LM; Pegg AE
Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
[TBL] [Abstract][Full Text] [Related]
11. A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts.
Bossù P; Vanoni M; Wanke V; Cesaroni MP; Tropea F; Melillo G; Asti C; Porzio S; Ruggiero P; Di Cioccio V; Maurizi G; Ciabini A; Alberghina L
Oncogene; 2000 Apr; 19(17):2147-54. PubMed ID: 10815806
[TBL] [Abstract][Full Text] [Related]
12. Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42.
Fidyk N; Wang JB; Cerione RA
Biochemistry; 2006 Jun; 45(25):7750-62. PubMed ID: 16784226
[TBL] [Abstract][Full Text] [Related]
13. Platelet-derived growth factor-induced p21ras-mediated signaling is independent of platelet-derived growth factor receptor interaction with GTPase-activating protein or phosphatidylinositol-3-kinase.
Burgering BM; Freed E; van der Voorn L; McCormick F; Bos JL
Cell Growth Differ; 1994 Mar; 5(3):341-7. PubMed ID: 8018566
[TBL] [Abstract][Full Text] [Related]
14. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
[TBL] [Abstract][Full Text] [Related]
15. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
Takeuchi M; Shichinohe T; Senmaru N; Miyamoto M; Fujita H; Takimoto M; Kondo S; Katoh H; Kuzumaki N
Gene Ther; 2000 Mar; 7(6):518-26. PubMed ID: 10757026
[TBL] [Abstract][Full Text] [Related]
16. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation.
Nur-E-Kamal MS; Kamal JM; Qureshi MM; Maruta H
Oncogene; 1999 Dec; 18(54):7787-93. PubMed ID: 10618719
[TBL] [Abstract][Full Text] [Related]
17. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
18. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
Cox AD; Brtva TR; Lowe DG; Der CJ
Oncogene; 1994 Nov; 9(11):3281-8. PubMed ID: 7936652
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
Senmaru N; Shichinohe T; Takeuchi M; Miyamoto M; Sazawa A; Ogiso Y; Takahashi T; Okushiba S; Takimoto M; Kato H; Kuzumaki N
Int J Cancer; 1998 Oct; 78(3):366-71. PubMed ID: 9766573
[TBL] [Abstract][Full Text] [Related]
20. Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.
Li W; Michieli P; Alimandi M; Lorenzi MV; Wu Y; Wang LH; Heidaran MA; Pierce JH
Oncogene; 1996 Aug; 13(4):731-7. PubMed ID: 8761294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
